N/A N=7 Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
Peptic Ulcer
Primary: Number of Participants Completing Natural Orifice Translumenal Endoscopic Surgical (NOTES) Repair — 2; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
N/A N=54 Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis
Erosive Gastritis
Primary: Changes in Erosions — 4.36; 3.38; 2.32; 2.43 erosions
Phase 2 N=37 Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome
Gastric Cancer · Gastric Neoplasms
Primary: Percentage of Participants With Detectable Confocal Endoscopic Microscopy (CEM) w/Greater Sensitivity for Detection of Signet Ring Cells (SRC)Foci in Cadherin-1 (CDH1)…
N/A N=93 Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment
Esophageal Lesion
Primary: Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy — 15 Participants
N/A N=1,490 Blood Tests for Gastritis and Gastric Neoplasms
Cancer Screening Tests
Primary: Significant Blood Test Findings Correlated With Gastric Neoplasms — 9.9; 6.5 score on a scale
Phase 2 N=18 Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
N/A N=44 A Diagnostic Study of the Advanced Endoscopy to Detect Early Esophageal Cancer
Esophageal Neoplasms
Primary: Accuracy — 89; 70 Percentage of accuracy
N/A N=5 Gastrectomy, Eating Behaviour and GLP-1
Gastric Cancer · Dumping Syndrome
Primary: Nadir Blood Glucose — 3; 4.4 mmol/l — p=0.008
Phase 2 N=91 Chemoprevention of Gastric Carcinogenesis
Gastric Cancer · Gastric Intestinal Metaplasia
Primary: The Difference in Cell DNA Damage, Based on Percent Positive Cells, Between Patients Treated With DFMO and Patients Treated With Placebo at 6 Months. — 5.07; 7.32…
N/A N=76 Proteiomic Fingerprints of Gastric Juice
Gastric Cancer
Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants
N/A N=100 Gastric Ultrasound
Surgery
Primary: Aspiration Risk Grade — 30; 30; 20; 9 Participants
N/A N=374 The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department
Gastroesophageal Reflux
Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Phase 2 N=14 Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma
Morbid Obesity
Primary: Primary Outcome: Change in Body Weight — 9.6 kg
N/A N=10 Transmitted Light Tissue Thickness Analysis (TiLTT)
Morbid Obesity
Primary: Number of Patients With Transmitted Light Intensity to Gastric Wall Thickness) — 10 Participants
Phase 2 N=248 A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
Erosive Esophagitis
Primary: Number of Patients With Esophageal Mucosa Healing — 28; 28; 32; 18 Participants
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
N/A N=24 Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
Gastrointestinal Stromal Tumors
Primary: Number of Patients Who Survived — 5 Participants
N/A N=10 Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance
Abdominal Adhesions
Primary: Completion of Diagnostic Peritineoscopy — 8 Participants
Phase 4 N=23 Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
Gastrointestinal Lesions · Signs and Symptoms, Digestive
Primary: GI Mucosal Lesions Change and Clinical Symptoms Using The Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.99; 2.19 GSRS score — p=0.05
N/A N=60 Perianastomotic Drain After Gastrectomy (DRAG)
Gastric Cancer
Primary: a) Number of Participants With High Pain Levels (Using the Visual Analog Scale) — 31; 3 Participants
N/A N=35 Gastric Tissue Stapler Comparison Study
Gastric Resection
Primary: Pressure Evaluation — 126; 163 mmHg
N/A N=126 Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia
Stomach Neoplasms · Metaplasia
Primary: Percent Agreement Between Acetic Acid Chromoendoscopy and Endoscopic Biopsy — 78.5; 94.4; 89.2; 67.1 percentage of lesions
N/A N=96 Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Primary: Complete Response — 81 Participants
Phase 2 N=33 Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Gastric Cancer
Primary: Number of Patients With Each Response in "Good Risk" Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression]) — 0…
Phase 2 N=78 Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material
Esophageal Adenocarcinoma
Primary: Number of Participants With Anastomotic Leak. — 10; 68 Participants
Phase 4 N=301 Post-marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer
Stomach Ulcer
Primary: Gastric Ulcer Healing Rate (Number of Subjects Whose Gastric Ulcer Was Healed/Number of Subjects Evaluated x 100) at Week 8 — 70.13; 60.54 percentage of participants
Phase 2 N=204 Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
Upper Gastrointestinal Mucosal Damage
Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants